Join
Live feed
·
PRReleasevia Quantisnow
Arcutis Biotherapeutics Inc. logo

Arcutis Announces Acceptance of Late Breaking Abstract in Atopic Dermatitis Among Five New Topical Roflumilast Data Being Presented at the American Academy of Dermatology Annual Meeting

ByQuantisnow·Wall Street's wire, on your screen.
ARQT· Arcutis Biotherapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ARQT (Arcutis Biotherapeutics Inc.) and more on Quantisnow.